Arsenic for low-risk MDS
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests an oral form of arsenic in people with low-risk myelodysplastic syndromes (MDS) who need regular red blood cell transfusions and haven't gotten enough benefit from standard treatments. It aims to see if this drug can help reduce transfusion needs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with low-risk MDS (very low, low, or intermediate risk).
- You need regular red blood cell transfusions (at least 3 transfusions in 16 weeks).
- You have tried or are not eligible for standard treatments like erythropoiesis-stimulating agents (ESA drugs), luspatercept, or lenalidomide.
- You are 18 years or older.
- You have adequate kidney and liver function, and no major heart problems.
- You have not had any active cancer (other than some skin cancers) in the last year.
- If you could become pregnant, you agree to use effective birth control and have regular pregnancy tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests R289 in adults with lower-risk myelodysplastic syndromes (MDS) whose disease keeps causing anemia and/or ongoing need for red blood cell transfusions. It may help reduce blood problems and treat MDS when standard options haven’t worked well enough or aren’t suitable.
This study tests whether adding arsenic trioxide to the usual stem cell transplant procedure can lower the risk of leukemia coming back. It is for people with high-risk AML or MDS who have a specific TP53 gene change.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
This trial compares three different medicines to see which works best for people with a blood condition called myelodysplasia (also called MDS) that causes anemia. It aims to find the safest and most effective option to improve blood counts and reduce symptoms like tiredness or shortness of breath.
Hear when a new Low Risk Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.